Key result
Utilization of advanced cardiovascular therapies was higher in New York than Ontario for EVAR (20.2 vs 12.8 per 100,000 adults), LVAD (1.3 vs 0.3), and TAVR (14.3 vs 6.6; all P<0.001).
Why the study?
EVAR, LVAD, and TAVR are expensive cardiovascular technologies with broad potential benefit, but few population-based studies have compared utilization between countries.
Does the utilization of advanced cardiovascular therapies (EVAR, LVAD, TAVR) differ between New York State and Ontario?
Cohort (n=16,899)
Yes
Does the utilization of advanced cardiovascular therapies (EVAR, LVAD, TAVR) differ between New York State and Ontario?
Utilization of advanced cardiovascular therapies including EVAR, LVAD, and TAVR is significantly higher in New York State compared to Ontario, Canada.
Answers are grounded in this paper and cite their sources.
Higher utilization in New York may reflect access or practice differences; leaves open appropriateness, outcomes, and drivers of regional variation.
Background: Endovascular aortic aneurysm repair (EVAR), left ventricular assist device (LVAD), and transcatheter aortic valve replacement (TAVR) are expensive cardiovascular technologies with potential to benefit large numbers of patients. There are few population-based studies comparing utilization between countries. Our objective was to compare patient characteristics and utilization patterns of EVAR, LVAD, and TAVR in Ontario, Canada, and New York State, United States. Methods and Results: We performed a retrospective cohort study using administrative data to identify all adults who received EVAR, LVAD, or TAVR in Ontario and New York between 2012 and 2015. We compared socio-demographics of EVAR, LVAD, and TAVR recipients in Ontario and New York. We compared standardized utilization rates between jurisdictions for each procedure. We identified 3295 EVAR recipients from Ontario and 6236 from New York (mean age 74.6 versus 74.5 years; P =0.61): 136 LVAD recipients from Ontario and 686 from New York (age, 57.4 versus 57.7 years; P =0.80): 1708 TAVR recipients from Ontario and 4838 from New York (age, 83.1 versus 83.1; P =1.0). A significantly smaller percentage of EVAR and TAVR recipients in Ontario were female compared to New York (EVAR, 15.8% versus 22.1% female; P <0.001; TAVR, 45.9% versus 51.8%; P <0.001), but for LVAD the percentage female was similar (21.3% versus 20.8%; P =0.99). Utilization was significantly higher in New York for all procedures: EVAR (12.8 procedures per-100 000 adults per-year in Ontario, 20.2 in New York; P <0.001); LVAD (0.3 in Ontario versus 1.3 in New York; P <0.001); and TAVR (6.6 in Ontario, 14.3 in New York; P <0.001). Higher utilization of EVAR and TAVR in New York relative to Ontario increased substantially with increasing age. Conclusions: We observed significantly higher utilization of EVAR, LVAD, and TAVR in New York compared to Ontario. Our results highlight important differences in how 2 different countries are using advanced cardiovascular therapies.
No takes yet. Share an insight, caveat, or question.
Cram et al. (2020) conducted a cohort in EVAR, LVAD, or TAVR recipients (n=16,899). New York State healthcare system vs. Ontario, Canada healthcare system was evaluated on Standardized utilization rates (procedures per 100,000 adults per year) (p=<0.001). Utilization of advanced cardiovascular therapies was higher in New York than Ontario for EVAR (20.2 vs 12.8 per 100,000 adults), LVAD (1.3 vs 0.3), and TAVR (14.3 vs 6.6; all P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: